ARA-290 Research Log – Two Subjects with Neuropathy and Chronic Pain

Thanks for posting this. Did the vial mixed with bacteriostatic water end up gelling? That happened with two vials from the same batch for me. Trying to locate PBS but it is hard to find where I live.

Too much information creates noise and feels like an exam. The reaction was probably due to the solution being hypotonic. When a bump appears right away there is little doubt. Adding sterile 0.9% NaCl should fix it. PBS is a good choice because it simplifies several things. Just calculate the right concentration so it stays in the suitable range. Needle length also matters. Planning to obtain some ARA this week after only a quick look at the literature so far.

No, the unbuffered version should work fine. It just requires a bit more effort during reconstitution, but once that is done it performs the same.

From what I have read, if it does not state that it is buffered then it is not. No difference in effectiveness, only that the buffered form is easier to reconstitute with bacteriostatic water.

Although the plan was to use only one compound, both subjects added BPC-157 site injections and KLOW for their specific problem areas. June 30 update: pH tested on both subjects’ compounds today. Subject A began ARA-290 on 6/25 at 2 mg, increased to 4 mg on 6/29, added BPC-157 at 0.5 mg twice daily to the mid/lower back, and started KLOW on 6/28. On 6/29 morning stood up straight for the first time in nearly eight years and walked four minutes without pain. On 6/30 walked six minutes without pain. Subject B started ARA-290 at 4 mg on 6/25, used BPC-157 at two sites, and began KLOW on 6/28. On 6/30 reported no improvement in nerve pain from left ankle to hip, slight overall improvement, and a new painful spot on the left thigh at the previous injection site.

ARA-290 is on the way and a dosing plan is being prepared. Sciatica has been present for years and at times caused complete immobility. Research indicates ARA-290 should be mixed by first adding PBS until the puck dissolves, then adding the desired amount of bacteriostatic water. 0.5 mL of PBS is the volume repeatedly mentioned for dissolving the puck. Possibly the 2 mL of PBS created the painful spot on Subject B’s thigh so quickly.

Thanks for sharing the testing. The method and presentation are appreciated.

This is the kind of information wanted here. Several months ago there was more of this type of detail, but things have changed.

It can be brought back. All of us are the human trials and sharing the data matters.

July 1 update: Subject A increased walk time by twelve seconds without pain. Subject B showed no changes. Both subjects’ vials were tested and the injection-site issues were traced to the PBS being at ten times the correct strength, which made the compounds painful. The referenced study used 4 mg to 8 mg doses and the proper PBS recipe of 20 mmol/L sodium phosphate buffer at pH 6.5 with 1% sucrose and 4% d-mannitol. Pharmacokinetic data showed a peak plasma level around 3 ng/mL after a 4 mg subcutaneous dose with a terminal half-life of about twenty minutes.

Thanks for sharing.

Tried 4 mg daily for about forty days for sciatica and peripheral neuropathy but unfortunately saw no effect.

My next report comes on the sixth of July. For the third, subject A managed these walking times and distances until back discomfort started: first day four minutes two seconds for fifteen hundredths of a mile, third day six minutes two seconds covering twenty two hundredths, fourth day six fourteen for twenty four hundredths, sixth day six fifty covering twenty nine hundredths. They mentioned feeling greater ease of movement prior to discomfort setting in. For subject B there was no improvement regarding left leg nerve discomfort. They mentioned their doctor endorses an operation as the underlying issue and plans scans to pinpoint it. On the positive side discomfort related sleep issues dropped by nearly half according to their watch data. The two participants get five additional ten milligram containers to mix using two milliliters of solution to reach the correct concentration. Acidity level checked prior to use. Dosing for both will stay at four milligrams each day.

Reconstituted ARA-290 with bacteriostatic water without issue and was unaware there might be a problem. No injection-site reaction occurred.

Used bacteriostatic water both times ARA was cycled. No issues and PBS was not needed.

Does Subject B have injection-site reactions only to the ARA or also to the KLOW? Is there any history of allergy or autoimmunity in Subject B?

July 6 update: Subject A has continued to extend pain-free walks in recent days though exact times were not recorded. Subject B’s newly reconstituted vial with 1 mL bacteriostatic water caused no site issues. Sleep tracking shows a 35% drop in pain-related wake-ups. Daytime nerve pain remains the same. The vial now shows proper pH of 7.1 and the 4 mg dose is 40 units.

Any new updates?

July 10 update: Both subjects completed two weeks of treatment, or nine days once incorrect-reconstitution days are removed. Subject A is on holiday and walking more each day with a few additional minutes of pain-free time reported. Subject B shows further improvement in sleep calmness with fewer interruptions from pain shocks. Daytime pain level unchanged.

Week of July 11-18: Both subjects continue daily 4 mg subcutaneous ARA-290 plus 4 mg KLOW and 1 mg BPC-157. BPC-157 site for Subject A is lower back; for Subject B it is above the knee on the nerve-impinged leg. Subject A continues to increase time until pain during walks, last logged at 6 minutes 22 seconds, and has asked to continue past 28 days if possible. Subject B reports no daytime improvement in left-leg nerve pain but sleep tracking shows a 60% reduction in awakening events and restlessness; sleep is described as significantly better and continuation past 28 days is also requested.

Hope things are still moving in a positive direction. Any updates would be welcome.

Following, this is useful information.